Ticker: SKBI, Company: SKYSTAR BIO-PHARMACEUTICAL CO, Type: 8-K, Date: 2010-05-12
Original SEC Filing: Click here

---

Webplus: SKBI/20100512/8-K/2_EX-99.1/000.htm SEC Original: v184608_ex99-1.htm
SKYSTARMMENCES TESTING ON TWODITIONAL NEW PRODUCT DOSAGE FORMS TO FURTHER EXPAND THEMPANYS PRODUCT LINES The new dosage forms projected to generate $5 million inditional revenue by fiscal 2011 XI’AN, CHINA May 12, 2010 -ystar Bio-Pharmaceuticalmpany (NASDAQ:SKBI) (“Skystar” or the “Company”), The product testing process will ensure that the new dosage forms willhere to good manufacturing

---

---

Webplus: SKBI/20100512/8-K/1/000.htm SEC Original: v184608_8k.htm
FORM 8-K CURRENT REPORTte of report (Date of earliest event reported): May 12, 2010YSTAR BIO-PHARMACEUTICALMPANY Nevada 001-34394 33-0901534 (State or other jurisdiction oforporation or organization) (Commission File No.) (IRS Employer Identification No.) Rm. 10601, Jiezuo Plaza, No.4, Fenghui Road South, Gaoxin District, Xian, Shaanxi Province, P.R. China

---

Company Information:

Ticker: SKBI, Company: SKYSTAR BIO-PHARMACEUTICAL CO, Type: 8-K, Date: 2010-05-12CIK: 0001076939, Location: F4, SIC: 2834, SIC Desc: PHARMACEUTICAL PREPARATIONS
Business Phone & Address:
RM 10601, JIEZUO PLAZA, NO. 4, FENGHUI ROAD SOUTH, GAOXIN DISTRICT
XIAN PROVINCE